» Articles » PMID: 15239019

Congenital Adrenal Hyperplasia - How to Improve the Transition from Adolescence to Adult Life

Overview
Specialty Endocrinology
Date 2004 Jul 9
PMID 15239019
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Congenital adrenal hyperplasia (CAH) is caused by a defect in the biosynthesis of cortisol that results in maximal activity of the hypothalamic-pituitary adrenal axis with hyperplasia of the adrenals and hyperandrogenism due to the accumulation of androgen precursors. In the salt-wasting subtype of the disorder, which accounts for appr. 75 % of patients with classical CAH, patients are unable to synthesise sufficient amounts of aldosterone and are prone to life-threatening salt-losing crises, whereas the simple virilising form is predominantly characterized by clitoris hypertrophy and posterior labial fusion. In addition, a non-classical variant can be discerned which in most cases is diagnosed at the time of puberty or early adolescence when hirsutism and menstrual irregularities may occur. The vast majority of CAH patients have 21-hydroxylase deficiency (90 - 95 %). Less common forms, such as 11beta-hydroxylase deficiency, will not be discussed in this review. Unfortunately, a considerable number of CAH patients is lost to regular and competent follow-up once they move out of paediatric care. This is most probably the result of insufficient co-operation between paediatric and adult endocrinologists at the time of transition from adolescence to adulthood. Furthermore, there is a lack of clinical guidance regarding psychosexual development in these patients. In this overview we will focus on special aspects of CAH treatment in adolescence and adulthood, and report on our 10-year experience with a transfer system for endocrine patients from paediatric to internal medical care, known as the "Kieler Modell". For practical purposes, we here provide charts for follow-up of CAH patients that can be adapted for use in any endocrine outpatient clinic.

Citing Articles

Comprehensive transition of care for polycystic ovary syndrome from adolescence to adulthood.

Simon S, Phimphasone-Brady P, McKenney K, Gulley L, Bonny A, Moore J Lancet Child Adolesc Health. 2024; 8(6):443-455.

PMID: 38552655 PMC: 11837223. DOI: 10.1016/S2352-4642(24)00019-1.


We mind your step: understanding and preventing drop-out in the transfer from paediatric to adult tertiary endocrine healthcare.

Davidse K, Van Staa A, Geilvoet W, van Eck J, Pellikaan K, Baan J Endocr Connect. 2022; 11(5).

PMID: 35521816 PMC: 9175586. DOI: 10.1530/EC-22-0025.


Management of the Female With Non-classical Congenital Adrenal Hyperplasia (NCCAH): A Patient-Oriented Approach.

Livadas S, Bothou C Front Endocrinol (Lausanne). 2019; 10:366.

PMID: 31244776 PMC: 6563652. DOI: 10.3389/fendo.2019.00366.


Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.

Speiser P, Arlt W, Auchus R, Baskin L, Conway G, Merke D J Clin Endocrinol Metab. 2018; 103(11):4043-4088.

PMID: 30272171 PMC: 6456929. DOI: 10.1210/jc.2018-01865.


Impact of transition on quality of life in patients with congenital adrenal hyperplasia diagnosed during childhood.

Bachelot A, Vialon M, Baptiste A, Tejedor I, Elie C, Polak M Endocr Connect. 2017; 6(7):422-429.

PMID: 28720594 PMC: 5551429. DOI: 10.1530/EC-17-0094.